Rachel Garlick and the story of Eris Biotech.
Eris' founders connect the venture to concerns they encountered about treatment toxicity and immune suppression. Their current research begins with mesothelioma and investigates a mechanism associated with tumour immune evasion. Garlick's immunology and cell therapy background supplies relevant professional context. The source describes a development thesis; statements about avoiding side effects or eliminating cancer are not established clinical outcomes and are not adopted as facts in this profile.
Public advice & further reading.
No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.
Suggest a first-person interview or essay ↗Sources & attribution.
- 01Eris Biotech — Y Combinator company and active founder profile
Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.
www.ycombinator.com
Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.
Request a correction or update ↗